Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether ...
Philadelphia, February 20, 2025 – Endomyocardial biopsy (EMB) is a valuable method for diagnosing a range of cardiac conditions, but there is a risk of complication due to its invasive nature.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results